Back to results
US 2020/0347148 A1Published application
Methods for enhancing and maintaining car-t cell efficacy
AssigneeBellicum Pharmaceuticals, Inc.
InventorsAaron Edward Foster, David Michael Spencer
Life of this patent
Estimating the term…
Abstract
The technology relates generally to the field of immunology and relates in part to compositions and methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to compositions and methods for enhancing and maintaining chimeric antigen receptor-expressing T cells, while reducing cytotoxic effects of CAR-T cell therapies
Claims24
A modified cell population, comprising modified T cells, wherein:
- the modified T cells comprise a polynucleotide that encodes a chimeric antigen receptor, wherein the chimeric antigen receptor comprises:
- (i) a transmembrane region;
- (ii) a T cell activation molecule;
- and
- (iii) an antigen recognition moiety
- wherein the ratio of CD8+ to CD4+ T cells in the modified cell population is 3:2 or greater.
3 more elements
The method of claim 23 wherein the neutrailizing agent is an antibody.
Dependencies are inferred from the claim text.